SUNNYVALE, Calif., Jan. 8 /PRNewswire/ -- FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced the appointment of Mark Page to the position of Vice President, Marketing. Mark previously held the position of Senior Director of Worldwide Marketing and International Sales at FlowCardia.
"The promotion of Mark to VP, Marketing is integral to our overall expansion plans for 2010. Mark's extensive experience in the medical device arena and team leadership abilities will allow us to broaden our product portfolio and clinical exposure with the CROSSER Catheter in the United States and select OUS markets," said Chris Barys, COO. "It is an exciting time at FlowCardia as we continue to grow and expand and we are looking forward to Mark's leadership in his new role."
Prior to joining FlowCardia in 2005 as employee #12, Mr. Page served as Group Marketing Manager for Boston Scientific / Neurovascular and has 15 years of experience in medical device sales and marketing. In his new role, Mr. Page will be responsible for developing a portfolio of products and physician training programs designed to further adoption of the CROSSER Catheter as frontline technology for crossing peripheral and coronary CTOs.
With over 8,000 CROSSER Catheter cases completed to date, several new product releases coming in 2010, and a significant increase in sales headcount, including the promotion of Jose Marques from Senior Field Sales Trainer to Regional Director of the newly created Southeast Region, FlowCardia is poised to attain market leadership in the CTO crossing device market in 2010.
About the CROSSER CTO Recanalization Catheter
The CROSSER CTO Recanalization Catheter is a minimally-invasive endovascular device that is delivered to the blockage within the artery using standard guidewire techniques. The doctor then energizes the CROSSER Catheter which utilizes high-frequency, mechanical vibration to pass through the blockage in the central lumen of the artery. Once the CROSSER Catheter passes through the occlusion, physicians can then perform standard atherectomy, balloon angioplasty and/or stent placement to optimize the longer term outcomes. For many patients, this minimally invasive approach to CTO recanalization can eliminate the need for a potentially traumatic bypass procedure or amputation.
FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture a portfolio of endovascular CTO recanalization products. Additional information is available on the company's web site at: www.flowcardia.com.
PR Contact Info: Michael Fanucchi FlowCardia, Inc. 408-617-0352 ext. 247
SOURCE FlowCardia, Inc.